<qa>  What is the effect of ARB treatment in patients with AVS that have undergone AVRRAAS hyperactivity may be attenuated pharmacologically using angiotensin converting enzyme inhibitors ACEi or angiotensin II receptor blockers ARB which in systemic hypertension with LV hypertrophy has been associated with reverse remodelling. This may at least partly be associated with increased collagenase activity and depressed collagen synthesis. Thus attenuation of RAAS hyperactivity may in theory lead to decreased myocardial fibrosis and improving the diastolic function of the LV. The effect of ARB treatment in patients with AVS that have undergone AVR is not known. 